Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, particularly those with unmet medical needs. The company has successfully commercialized three vaccines, including the world's first chikungunya vaccine, and is advancing a diverse pipeline of vaccine candidates targeting diseases such as Lyme disease, Shigella, and Zika. Valneva employs a specialized approach to vaccine development, utilizing various modalities to create first-, best-, or only-in-class solutions. Their commitment to innovation is evident in their collaboration with LimmaTech Biologics for the development of a tetravalent Shigella vaccine candidate, which is currently undergoing a Phase 2b human challenge study.

In addition to vaccine development, Valneva has established a robust commercial infrastructure for the distribution of its travel vaccines, which accounts for a significant portion of its annual revenue. The company emphasizes the use of digital technology to enhance connections with travelers, healthcare professionals, and physicians, ensuring that customer needs are prioritized. Valneva's partnerships with other companies, such as Seqirus and Bavarian Nordic, further expand its product offerings in the flu vaccine market and other areas. Overall, Valneva's strategic focus on addressing global health challenges through innovative vaccine solutions positions it as a key player in the biotechnology sector.

France

Valneva is a specialty vaccine company providing prevention against diseases with major unmet medical needs. The Company has a growing commercial business with two successful vaccines for travelers. Our focused pipeline includes the only Lyme disease vaccine candidate in clinical development today, a single-shot chikungunya vaccine candidate and an inactivated vaccine candidate against COVID-19.

Cancer

Endocrine System Diseases

Hematologic Diseases

Metabolic Diseases

Valneva SE

Chikungunya

Infectious disease

VLA1553 is a monovalent, single dose, live-attenuated vaccine &nbsp;candidate for protection against chikungunya. VLA1553 is based on an &nbsp;infectious clone (CHIKV LR2006-OPY1) attenuated by deleting a major part &nbsp;of the gene encoding the non-structural replicase complex protein nsP3, &nbsp;aiming for protection against various chikungunya virus outbreak &nbsp;phylogroups and strains<a href="https://valneva.com/press-release/valneva-initiates-phase-3-clinical-study-for-its-chikungunya-vaccine-candidate-vla1553/#_ftn5">[5]</a>.
The vaccine candidate is designed for prophylactic, active, &nbsp;single-dose immunization against chikungunya. As a live-attenuated &nbsp;vaccine, VLA1553 is particularly well suited to target long-lasting &nbsp;protection.&nbsp; The safety profile is anticipated to be similar to licensed &nbsp;vaccines for active immunization in adults and children.
<a href="https://valneva.com/press-release/valneva-initiates-phase-3-clinical-study-for-its-chikungunya-vaccine-candidate-vla1553/">Source</a>

IXCHIQ (VLA1553)

Viral infection

Bacterial infection

Lyme disease

VLA15 is a multivalent, protein subunit vaccine that targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for Lyme disease vaccine. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick (<a href="https://valneva.com/research-development/lyme-disease/">learn more HERE</a>).&nbsp;

VLA15

Nasolabial fold lines

Shigella

Shigella4V2 (S4V2) 

Zika virus

VLA1601

COVID-19

VLA2001 is a Vero-cell based, highly-purified inactivated whole virus vaccine candidate.
VLA2001 is the first inactivated COVID-19 vaccine in clinical development in Europe.
The inactivated vaccine is a proven approach that has been used for decades.<a href="https://valneva.com/research-development/covid-19-vla2001/#_ftn1">[1]</a>
An inactivated SARS-CoV-2 vaccine would be suitable for wide deployment including particularly vulnerable populations.

Valneva SE

Company Details